SNGX News and Press, Soligenix Inc. From 01/14/20

PRINCETON, N.J. , Jan. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update let...

These Penny Stocks Are Rocking But Can That Continue? One of the biggest reasons behind the popularity of penny stocks is the fact that you can make big money with smaller investments. Therefore, investors are almost always on the lookout for the next big penny stocks to buy . However, in o...

PRINCETON, N.J. , Dec. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it ha...

New York, New York--(Newsfile Corp. - December 13, 2019) - This news release has been corrected to add legal disclaimers. As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix  (NASDAQ: SNGX) has achieved multiple milestones across the company's co...

Soligenix (NASDAQ: SNGX ) has opened Phase 1C study to evaluate the safety and immunogenicity of RiVax in healthy, normal adults, followed by a 6-month follow-up period. More news on: Soligenix, Inc., Healthcare stocks news, Read more ...

PRINCETON, N.J. , Dec. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it ha...

New York, New York--(Newsfile Corp. - December 11, 2019) - As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix  (NASDAQ: SNGX) has achieved multiple milestones across the company's core focus areas. Two treatments in development to treat rare disea...

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today completion of patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (&#...

Soligenix (NASDAQ: SNGX ) has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). More news on: Soligenix, Inc., Healthcare stocks news, ...

PRINCETON, N.J. , Dec. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed...